Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 279 participants.
Also called NCT05619653
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 279 participants
- Sponsor
- Registry
-
NCT05619653 -
2022-001682-12
-
- Other papers using this trial's data
- Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Austria, Germany
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05619653. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-12 (actual); primary completion 2025-08-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
- Acronym
- MYOFLAME-19
- Condition
- COVID-19 Associated Cardiac Involvement
- Condition
- Remodeling, Left Ventricle
- Condition
- Remodeling, Vascular
- Condition
- Left Ventricular Dysfunction
- Condition
- Exercise Intolerance
- Condition
- Vascular Inflammation
- Condition
- Microvascular Angina
- Condition
- Long COVID
- Condition
- Myocarditis, Pericarditis
- Intervention (Drug)
- Prednisolone
- Intervention (Drug)
- Losartan
- Lead sponsor
- Valentina Puentmann
- Collaborator
- Bayer
- Collaborator
- Alcedis GmbH
Record details
- Record id
cardio:ct-nct05619653- Content hash
9dbc359f40eb0b1bdbb12467fbcccc060c01a056b9b430afb1cbfde2fdaf33ab